Want to see VBIO full AI Analyst Report?
Total Valuation
Valion Bio has a market cap or net worth of $2.72M. The enterprise value is $24.70.
Market Cap$2.72M
Enterprise Value$24.70
Share Statistics
Valion Bio has 22,189,740 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding22,189,740
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Valion Bio’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee7.35K
Profits Per Employee-35.26K
Employee Count52
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Valion Bio is ―. Valion Bio’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio0.00
Income Statement
In the last 12 months, Valion Bio had revenue of 382.00K and earned 0.00 in profits. Earnings per share was 0.00.
Revenue382.00K
Gross Profit32.00K
Operating Income-768.00K
Pretax Income0.00
Net Income0.00
EBITDA-768.00K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 964.82K and capital expenditures 0.00, giving a free cash flow of 964.82K billion.
Operating Cash Flow964.82K
Free Cash Flow964.82K
Free Cash Flow per Share0.04
Dividends & Yields
Valion Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.76
52-Week Price Change-96.16%
50-Day Moving Average0.39
200-Day Moving Average1.03
Relative Strength Index (RSI)24.51
Average Volume (3m)99.84K
Important Dates
Valion Bio upcoming earnings date is Nov 13, 2026, Before Open (Confirmed).
Last Earnings DateAug 17, 2026
Next Earnings DateNov 13, 2026
Ex-Dividend Date―
Financial Position
Valion Bio as a current ratio of 0.57, with Debt / Equity ratio of ―
Current Ratio0.57
Quick Ratio0.57
Debt to Market Cap0.00
Net Debt to EBITDA1.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Valion Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Valion Bio EV to EBITDA ratio is 1.02, with an EV/FCF ratio of 0.80.
EV to Sales-2.05
EV to EBITDA1.02
EV to Free Cash Flow0.80
EV to Operating Cash Flow0.80
Balance Sheet
Valion Bio has $285.39K in cash and marketable securities with $400.00K in debt, giving a net cash position of -$14.61K billion.
Cash & Marketable Securities$285.39K
Total Debt$400.00K
Net Cash-$14.61K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.00
Margins
Gross margin is ―, with operating margin of -201.05%, and net profit margin of 0.00%.
Gross Margin―
Operating Margin-201.05%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin-201.05%
EBIT Margin0.00%
Analyst Forecast
The average price target for Valion Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-49.63%
EPS Growth Forecast82.22%